<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03252600</url>
  </required_header>
  <id_info>
    <org_study_id>2016-200</org_study_id>
    <secondary_id>NCI-2017-01203</secondary_id>
    <secondary_id>2016-200</secondary_id>
    <secondary_id>P30CA022453</secondary_id>
    <nct_id>NCT03252600</nct_id>
  </id_info>
  <brief_title>Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis</brief_title>
  <official_title>A Randomized Phase 2 Trial of Lenalidomide/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide Followed by Lenalidomide/ Dexamethasone/Elotuzumab Maintenance as Second-Line Therapy for Patients With Relapsed AL Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Multiple Myeloma Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well lenalidomide, dexamethasone, and eotuzumab&#xD;
      with or without cyclophosphamide work in treating patients with primary amyloidosis that has&#xD;
      come back after a period of improvement. Drugs used in chemotherapy, such as lenalidomide,&#xD;
      dexamethasone, and cyclophosphamide, work in different ways to stop the growth of cancer&#xD;
      cells, either by killing the cells, by stopping them from dividing, or by stopping them from&#xD;
      spreading. Monoclonal antibodies, such as eotuzumab, may interfere with the ability of cancer&#xD;
      cells to grow and spread. Giving lenalidomide, dexamethasone, and eotuzumab with&#xD;
      cyclophosphamide may work better in treating patients with primary amyloidosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the rate of hematologic response of very good partial response (VGPR) or better&#xD;
      according to the International Society of Amyloidosis (ISA) hematologic response criteria.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess duration of hematologic response. II. To assess time to hematologic progression.&#xD;
      III. To assess overall hematologic response rate. IV. To assess complete hematologic response&#xD;
      rate. V. To assess organ response (according to ISA organ response criteria). VI. To assess&#xD;
      overall survival (OS).&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive lenalidomide orally (PO) on days 1-21 and dexamethasone intravenously&#xD;
      (IV) on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on days 1, 8,&#xD;
      15, and 22 of courses 1 and 2 and days 1 and 15 of subsequent courses. Treatment repeats&#xD;
      every 28 days for up to 6 courses in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      ARM II: Patients receive lenalidomide, dexamethasone, and elotuzumab as in Arm I. Patients&#xD;
      also receive cyclophosphamide IV on days 1, 8, and 15. Treatment repeats every 28 days for up&#xD;
      to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      MAINTENANCE THERAPY: All patients receive lenalidomide PO on days 1-21 and dexamethasone IV&#xD;
      on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on day 1. Courses&#xD;
      repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 25, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major hematologic response (&gt;= very good partial response), or better</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Will be expressed as a proportion with Clopper-Pearson exact 95% confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody parameters</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Will be reported with descriptive statistics including 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Will be reported with descriptive statistics including 95% confidence intervals and will be estimated using Kaplan-Meier methods for median time to event data and 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hematologic response</measure>
    <time_frame>The time from the first date a hematologic response is documented to the date of the first documented hematologic progression assessed up to 24 months</time_frame>
    <description>Will be reported with descriptive statistics including 95% confidence intervals and will be estimated using Kaplan-Meier methods for median time to event data and 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ response</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Will be assessed by the investigator and reported in the electronic case report form and reported with descriptive statistics including 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Will be reported with descriptive statistics including 95% confidence intervals and will be estimated using Kaplan-Meier methods for median time to event data and 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Will be reported with descriptive statistics including 95% confidence intervals and will be estimated using Kaplan-Meier methods for median time to event data and 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hematologic progression</measure>
    <time_frame>The time from the first date of first dose to the date of the first documented hematologic progression assessed up to 24 months</time_frame>
    <description>Will be reported with descriptive statistics including 95% confidence intervals.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Recurrent Primary Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Arm I (lenalidomide, dexamethasone, elotuzumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on days 1, 8, 15, and 22 of courses 1 and 2 and days 1 and 15 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE THERAPY: Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II(lenalidomide,dexamethasone,elotuzumab,cyclophosphamide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive lenalidomide, dexamethasone, and elotuzumab as in Arm I. Patients also receive cyclophosphamide IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE THERAPY: Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II(lenalidomide,dexamethasone,elotuzumab,cyclophosphamide)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (lenalidomide, dexamethasone, elotuzumab)</arm_group_label>
    <arm_group_label>Arm II(lenalidomide,dexamethasone,elotuzumab,cyclophosphamide)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Elotuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (lenalidomide, dexamethasone, elotuzumab)</arm_group_label>
    <arm_group_label>Arm II(lenalidomide,dexamethasone,elotuzumab,cyclophosphamide)</arm_group_label>
    <other_name>BMS-901608</other_name>
    <other_name>Empliciti</other_name>
    <other_name>HuLuc-63</other_name>
    <other_name>HuLuc63</other_name>
    <other_name>PDL-063</other_name>
    <other_name>PDL063</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (lenalidomide, dexamethasone, elotuzumab)</arm_group_label>
    <arm_group_label>Arm II(lenalidomide,dexamethasone,elotuzumab,cyclophosphamide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (lenalidomide, dexamethasone, elotuzumab)</arm_group_label>
    <arm_group_label>Arm II(lenalidomide,dexamethasone,elotuzumab,cyclophosphamide)</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>CC5013</other_name>
    <other_name>CDC 501</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (lenalidomide, dexamethasone, elotuzumab)</arm_group_label>
    <arm_group_label>Arm II(lenalidomide,dexamethasone,elotuzumab,cyclophosphamide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy-proven histochemical diagnosis of amyloid light-chain (AL) amyloidosis based on&#xD;
             tissue specimens with Congo red staining or other histologic stain; thioflavin T or S,&#xD;
             or crystal violet; tandem mass spec or immunohistochemistry (IHC) confirmation of&#xD;
             immunoglobulin-derived amyloidosis is encouraged; cases in which histochemical&#xD;
             confirmation is lacking need to be discussed with one of the Multiple Myeloma Research&#xD;
             Foundation (MMRF) protocol chair/co-chairs&#xD;
&#xD;
          -  One prior line of therapy (defined as either one non-transplant regimen such as&#xD;
             MelDex, Vel-Dex or CyBorD, one autologous stem cell transplant, or one regimen of&#xD;
             non-transplant induction therapy followed by a single autologous stem cell transplant&#xD;
             (without hematologic progression between induction and autologous stem cell transplant&#xD;
             [ASCT])&#xD;
&#xD;
          -  Measurable hematologic disease as defined by:&#xD;
&#xD;
               -  Serum differential free light chain concentration (dFLC, difference between&#xD;
                  amyloid forming [involved] and non-amyloid forming [uninvolved] free light chain&#xD;
                  [FLC]) &gt;= 50 mg/L)&#xD;
&#xD;
          -  Objective measurable (cardiac, renal or liver) organ amyloid involvement defined as&#xD;
             follows (amyloid involvement of at least 1 required):&#xD;
&#xD;
               -  Mean wall thickness &gt; 12 mm on echocardiogram, with no other cardiac cause or an&#xD;
                  elevated NT-ProBNP (&gt; 332 ng/L) in the absence of renal failure or atrial&#xD;
                  fibrillation&#xD;
&#xD;
               -  Renal involvement is defined as proteinuria (predominantly albumin) &gt; 0.5 g/day&#xD;
                  in a 24-hour urine collection&#xD;
&#xD;
               -  Total liver span &gt; 15 cm in the absence of heart failure or alkaline phosphatase&#xD;
                  &gt; 1.5 times institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  NOTE: Amyloid involvement of other organ systems is allowed, but not required&#xD;
&#xD;
          -  Life expectancy of &gt;= 6 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  . Female subjects who are of non-reproductive potential (i.e., post-menopausal by&#xD;
             history for at least 24 consecutive months; OR history of hysterectomy; OR history of&#xD;
             bilateral tubal ligation; OR history of bilateral oophorectomy).Female of child&#xD;
             bearing potential (FCBP) must have a negative serum or urine pregnancy test with a&#xD;
             sensitivity of at least 25 mIU/mL or equivalent units of human chorionic gonadotropin&#xD;
             (hCG) within 10 ? 14 days prior to and again within 24 hours of starting lenalidomide&#xD;
             and study drug and must either commit to continue abstinence from heterosexual&#xD;
             intercourse or begin TWO acceptable methods of birth control, one highly effective&#xD;
             method and one additional effective method AT THE SAME TIME, at least 4 weeks before&#xD;
             she starts taking lenalidomide through 4 weeks after the last dose of lenalidomide and&#xD;
             5 half-lives after elotuzumab plus 30 days (duration of ovulatory cycle) for a total&#xD;
             of 180 days post-last dose of elotuzumab; FCBP must also agree to ongoing pregnancy&#xD;
             testing during the entire duration of treatment. Males must agree to use a latex or&#xD;
             synthetic condom during sexual contact with a FCBP even if they have had a vasectomy&#xD;
             from the time of signing the informed consent form through 28 days after the last dose&#xD;
             of lenalidomide and 5 half-lives of elotuzumab plus 90 days (duration of sperm&#xD;
             turnover) for a total of 180 days post-last dose of elotuzumab; these same patients&#xD;
             must not donate sperm; all patients must be counseled at a minimum of every 28 days&#xD;
             about pregnancy precautions and risks of fetal exposure; all patients prior to taking&#xD;
             lenalidomide, must be registered in and must comply with all requirements of the&#xD;
             lenalidomide Risk Evaluation and Mitigation Strategies (REMS) program&#xD;
&#xD;
          -  Ability to understand the purpose and risks of the study and provide signed and dated&#xD;
             informed consent and authorization to use protected health information&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,000 cells/mm^3 (1.0 x 10^9/L)&#xD;
&#xD;
          -  Platelet count &gt;= 75,000 cells/mm^3 (75 x 10^9/L)&#xD;
&#xD;
          -  Hemoglobin &gt;= 8.0 g/dl (red blood cell [RBC] transfusions are permitted)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x ULN (except if the patient has Gilbert?s syndrome who can&#xD;
             have total bilirubin =&lt; 2 x ULN)&#xD;
&#xD;
          -  Alkaline phosphatase =&lt; 5 x ULN&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and&#xD;
             alanine aminotransaminase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 3.0&#xD;
             x ULN&#xD;
&#xD;
          -  Renal function: creatinine clearance by Cockcroft-Gault formula &gt;= 30 mL/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Amyloidosis due to mutations of the transthyretin gene or presence of other non-AL&#xD;
             amyloidosis; exception: patients with amyloid heavy (AH) or mixed AL/AH type&#xD;
             amyloidosis are potentially eligible&#xD;
&#xD;
          -  Peripheral neuropathy &gt;= grade 3 sensory neuropathy or &gt;= grade 2 sensory neuropathy&#xD;
             with pain within 14 days of registration; prior neuropathy of this severity improved&#xD;
             due to medical management such as gabapentin are potentially eligible&#xD;
&#xD;
          -  Cardiac stage 2 or 3 with N-terminal prohormone (NT-pro)-B-type natriuretic peptide&#xD;
             (BNP) &gt; 8500 ng/L&#xD;
&#xD;
          -  Medically documented cardiac syncope, uncompensated New York Heart Association (NYHA)&#xD;
             class 3 or 4 congestive heart failure, myocardial infarction within the previous 6&#xD;
             months, unstable angina pectoris, uncontrolled hypertension (defined as an average&#xD;
             systolic blood pressure [SBP] over 140 or a diastolic blood pressure [DBP] over 90&#xD;
             despite antihypertensive agents), clinically significant repetitive ventricular&#xD;
             arrhythmias despite antiarrhythmic treatment, or severe orthostatic hypotension or&#xD;
             clinically important autonomic disease; prior to study entry, any electrocardiogram&#xD;
             (ECG) abnormality at screening has to be documented by the investigator as not&#xD;
             medically relevant; NOTE: there is no lower limit of left ventricular ejection&#xD;
             fraction below which patients are excluded from participation&#xD;
&#xD;
          -  Any medical conditions that, in the investigator?s opinion, would impose excessive&#xD;
             risk to the patient or would adversely affect his/her participating in this study,&#xD;
             including:&#xD;
&#xD;
          -  Known active infection requiring parenteral anti-infective treatment at the time of&#xD;
             initiation of treatment&#xD;
&#xD;
          -  Other malignancy diagnosed or requiring treatment within the past 3 years with the&#xD;
             exception of adequately treated basal cell carcinoma, squamous cell skin cancer,&#xD;
             carcinoma in-situ of the cervix or breast, or low-risk Gleason grade =&lt; 6 localized&#xD;
             prostate cancer not requiring therapy&#xD;
&#xD;
          -  Pregnant or breast-feeding females&#xD;
&#xD;
          -  Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or&#xD;
             confuse compliance or follow-up evaluation&#xD;
&#xD;
          -  Known or active human immunodeficiency virus (HIV) infection or active hepatitis B or&#xD;
             C viral infection&#xD;
&#xD;
          -  Cerebrovascular accident (CVA) with persistent neurologic deficits occurring within 6&#xD;
             months prior to enrollment; persisting neurologic deficits from a CVA occurring over 6&#xD;
             months prior to enrollment are not necessarily grounds for exclusion&#xD;
&#xD;
          -  Concurrent multiple myeloma (defined according to 2015 International Myeloma Working&#xD;
             Group [IMWG] guidelines)&#xD;
&#xD;
          -  POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly,&#xD;
             endocrinopathy, monoclonal protein [M-protein] and skin changes)&#xD;
&#xD;
          -  Previous cytotoxic therapies, including cytotoxic investigational agents, within 3&#xD;
             weeks (6 weeks nitrosoureas) prior to start of study treatment; previous&#xD;
             corticosteroids used with intent to treat amyloidosis within three weeks; (prednisone&#xD;
             up to but no more than 10 mg orally once a day [q.d.] or its equivalent for symptom&#xD;
             management of comorbid conditions is permitted but dose should be stable for at least&#xD;
             7 days prior to study treatment)&#xD;
&#xD;
          -  Residual side effects to previous therapy &gt; grade 1 prior to initiation of therapy&#xD;
             (alopecia any grade and/or neuropathy grade 2 without pain are permitted)&#xD;
&#xD;
          -  Prior autologous or allogeneic stem cell transplant within 12 weeks of initiation of&#xD;
             therapy&#xD;
&#xD;
          -  Prior allogeneic stem cell transplant within 16 weeks of initiation of therapy, or at&#xD;
             any time if patient has active graft-versus-host-disease (GVHD)&#xD;
&#xD;
          -  Prior major surgical procedure or radiation therapy within 4 weeks of the first dose&#xD;
             of study treatment (this does not include limited course of radiation used for&#xD;
             management of bone pain within 7 days of first dose of study therapy)&#xD;
&#xD;
          -  Known intolerance to steroid therapy (defined as being unable to tolerate at least 20&#xD;
             mg dex/week)&#xD;
&#xD;
          -  Inability to tolerate prophylactic anti-thrombotic therapy&#xD;
&#xD;
          -  &gt;= grade 3 thromboembolic event in the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Zonder, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>August 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2017</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Jeffrey Zonder</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Light-chain Amyloidosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Elotuzumab</mesh_term>
    <mesh_term>Ichthammol</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

